TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT

Myelodysplastic Syndrome Clinical Trial

Official title:

Multi-Institutional Pilot Study of Total Body Irradiation Using Intensity Modulated Radiation Therapy (IMRT) (VMAT or Tomotherapy) for Allogeneic HSCT With New Lung Radiation Dose Guidelines to Prevent Pul Toxicities

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04281199
• Other study ID #: 19508
• Secondary ID: NCI-2019-0895719
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: February 28, 2020
• Est. completion date: December 30, 2024

Study information

• Verified date: March 2024
• Source: City of Hope Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial studies how well radiation therapy techniques, volumetric modulated arc therapy (VMAT) and tomotherapy, work to reduce doses to the lung compared to standard total body irradiation methods to prevent pulmonary toxicities. Standard total body irradiation is limited in its ability to spare normal organs, with only the lung being partially spared by lung blocks and risks the development of pulmonary toxicities. Reducing the doses to the lung using VMAT or tomotherapy may improve survival and decrease long term lung side effects in patients undergoing stem cell transplant.

Description:

PRIMARY OBJECTIVES:

I. To test whether the investigators can achieve a mean lung dose of < 8 Gy and still treat the total body at a minimum of 85% prescribed dose in patients undergoing allogeneic hematopoietic stem cell transplantation who are eligible for standard total body irradiation (TBI)-based myeloablative regimens.

II. To evaluate TBI coverage from tomotherapy and VMAT with new lung sparing guidelines.

III. To assess the rate of adverse events with intensity-modulated radiation therapy (IMRT) TBI: type, frequency, severity, attribution, time course, duration, and complications (acute graft versus host disease [GvHD], infections, and delayed neutrophil/platelet engraftment) measured by Bearman and Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0.

SECONDARY OBJECTIVES:

I. To evaluate dose homogeneity for all target and non-target structures using dose volume histograms.

II. To evaluate non-relapse mortality at 100 days, and 1 year post IMRT TBI. III. To evaluate relapse-free survival (RFS) at 100 days, and 1 year post IMRT TBI.

IV. To evaluate extramedullary recurrence rate at 1 year post IMRT TBI.

OUTLINE:

Patients undergo TBI using IMRT with VMAT or tomotherapy twice daily (BID) on days -7 to -4 then undergo stem cell transplantation on day 0.

After completion of study treatment, patients are followed up at 100 days and 1 year post transplant.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20
• Est. completion date: December 30, 2024
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 60 Years

Eligibility

Inclusion Criteria:

• Karnofsky performance status (KPS) >= 70

• Acute leukemia or myelodysplastic patients evaluated within 30 days of start of conditioning regimen who would be candidates for TBI-cyclophosphamide (Cy) or TBI-etoposide (VP16) per City of Hope (COH) standard operating procedure (SOP) for allogeneic hematopoietic stem cell transplant

• Patients must be suitable for TBI conditioning regimens as part of transplant per the referring hematologist

• Patients must have adequate organ function for hematopoietic cell transplantation (HCT) as determined by the hematologist

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation

• All subjects must have the ability to understand the treatment and the willingness to sign a written informed consent

• The effects of total body radiation on the developing fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately

• Although not mandated by the protocol, the results of the imaging scans and labs (complete blood count [CBC], comprehensive metabolic panel [CMP]) that are performed as part of the standard work up should be available and should have been done within 2 months prior to study entry

• Prior therapy (chemotherapy, immunotherapy, radiotherapy) must be completed at least 2 weeks prior to TBI

• All patients with prior radiotherapy need to be reviewed with the principal investigator (PI) to determine eligibility

• Prior therapy with chemotherapeutic agents is allowed

• DONOR: Donor evaluation and eligibility will be assessed per current COH standard operating procedure

Exclusion Criteria:

• Patients should not have any uncontrolled illness including ongoing or active infection

• Prior history of radiation therapy must be presented to study PI for eligibility determination

• Pregnant women are excluded from this study because total body irradiation is an agent with the potential for teratogenic or abortifacient effects

• Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Related Conditions & MeSH terms

• Acute Leukemia
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes

Intervention

Procedure:
• Hematopoietic Cell Transplantation
Undergo HCT

Radiation:
• Intensity-Modulated Radiation Therapy
Undergo IMRT
• Tomotherapy
Undergo IMRT with tomotherapy
• Total-Body Irradiation
Undergo TBI
• Volume Modulated Arc Therapy
Undergo IMRT with VMAT

Locations

Country	Name	City	State
United States	City of Hope Medical Center	Duarte	California

Sponsors (2)

Lead Sponsor	Collaborator
City of Hope Medical Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Completion of all fractions of intensity-modulated radiation therapy (IMRT) total body irradiation (TBI) (volume modulated arc therapy or tomotherapy)	Will be summarized using percentage and its 95% confidence interval.	Up to 1 year post transplant
Secondary	Dose homogeneity for all target and non-target structures	Will use dose volume histograms.	Up to 1 year post transplant
Secondary	Rate of adverse events with IMRT TBI	Type, frequency, severity, attribution, time course, duration, and complications will be measured by Bearman and Common Terminology Criteria for Adverse Events version 5.0. Tables will be constructed to summarize the observed incidence, severity, and type of toxicity, including infection.	Up to 1 year post transplant
Secondary	Rate of complications with IMRT TBI	Will include acute graft versus host disease (aGVHD), infections, delayed neutrophil/platelet engraftment. Cumulative incidence rate will be used for aGVHD, and chronic GVHD.	Up to 1 year post transplant
Secondary	Non-relapse mortality	Cumulative incidence rate will be used.	From start of therapy until non-disease related death, or last follow-up, whichever comes first, assessed at 100 days and 1 year
Secondary	Extramedullary recurrence		From start of therapy, assessed at 1 year
Secondary	Relapse free survival	Kaplan-Meier curves will be used.	From start of therapy, assessed at 100 days and 1 year